| 摘要 |
<p>The present invention relates to the use of known and novel compounds as inhibitors of UDP-G1cNAc:Gal.beta.1,3GalNAc-R (GlcNAc to GalNAc) .beta.1,6-N-acetylglucosaminyl transferase (core 2 .beta.1,6 N-acetylaminotransferase, core 2 GlcNAc-T -EC 2.4.1.102). Such inhibitors have applications in therapy for diseases associated with raised activity of core 2 GlcNAc-T, in particular inflammatory diseases, atherosclerosis, diabetic cardiomyopathy, cancers -including treatment or prevention of metastasis - or diabetic retinopathy.</p> |
